Name:                Gabriel I. Barbash, M.D., M.P.H.
Position:            Director General, Tel-Aviv Sourasky Medical Center
E-mail:                gabi@tasmc.health.gov.il

EDUCATION:
1969 - 1975 -    Hebrew University, Jerusalem, Hadassah Medical School,

                             M.D. Degree received December 1975.
1980 - 1984 -    Residency in Internal Medicine, Tel Aviv Sourasky Medical Center.

                            Passed the Israeli Board examinations in Internal Medicine, May 1984, Summa Cum Laude.
1985 - 1986 -    Clinical - Administrative Residency Administration & Cardiology Department  

                            Beth Israel Hospital, Boston, Massachusetts.
1987 -                Passed the Israeli Board of Medical Management.
1991 -                Passed the Israeli Board of Occupational Medicine.

FURTHER STUDIES:
1983 - 1984 -    Tel Aviv University Medical School - One year program, Computers in Medicine.
1984 - 1985 -    Harvard University, School of Public Health -

                            Master in Public Health with concentration in Health Policy and Management, June 1985

ACADEMIC EXPERIENCE:
1986 - 1993 -    Teaching the course on Medical Information Systems,

                             in the master program of the Kovens Center for Management of Health Care Systems

                             in the Rekanati School of Business Administration, Tel Aviv University.
1987 - 1988 -    Co-coordinator of the course on Bio-medical Ethics

                             in the post-graduate school of the Sackler School of Medicine in Tel Aviv University.
1988 - 1990 -    Appointed lecturer in the Department of Epidemiology and Preventive Medicine

                            in the Sackler School of Medicine, Tel Aviv University.
1989 - 1993 -    Teaching the course in Epidemiology

                             in the Master program of the Kovens Center for Management of Health Care Systems

                             in the Rekanati School of Business Administration, Tel Aviv University.
1990 - 1994 -    Appointed senior lecturer in the Department of Epidemiology and Preventive Medicine

                            in the Sackler School of Medicine, Tel Aviv University.
1994 -                Appointed Associate Professor in the Department of Epidemiology and Preventive Medicine

                            in the Sackler School of Medicine, Tel Aviv University.

COORDINATION OF CLINICAL TRIALS:
1986 - 1989 -    Principal investigator & Chief Coordinator of the “Israeli Study of Early Intervention

                            in Acute Myocardial Infarction”, involving the Tel Aviv and Sheba Medical Centers.

                             Operating Budget - 750,000 DM.
1989 - 1990 -    National Coordinator and principal investigator of the International rt-PA/STK

                            Mortality Trial (GISSI- II) involving all the intensive coronary care units in Israel.

                            Operating Budget - $650,000.
1991 - 1993 -    National Coordinator and principal investigator of the GUSTO-I Study 

                             (an FDA audited trial) of thrombolytic therapy in AMI 

                             involving all the intensive coronary care units in Israel.

                             Operating Budget - $1,200,000.
1994 - 1995 -    National Coordinator and principal investigator of the TIMI-9 Study, Hirudin versus Heparin,

                            (an FDA audited trial) in AMI involving all the intensive coronary care units in Israel.

                             Operating Budget - $860,000.
1997 - 1998    - National Coordinator and principal investigator of the ASSENT II Study,

                            Thrombolytic Therapy trial, (an FDA audited trial)

                             in AMI involving all the intensive coronary care units in Israel.

                            Operating Budget - over $3,000,000.

CLINICAL & ADMINISTRATIVE EXPERIENCE:
1976 - 1978    - Flight Surgeon, Israeli Air Force. Deputy Surgeon General, Israeli Air Force.
1978 - 1979    - Coordinator of the Emergency Medical Services - Israel International “Ben-Gurion” Airport.
1980 - 1983    - Physician of the Combined Air-ground Operations’ Command - Israeli Air Force.
1980 - 1984    - Deputy Director - The Sheba Medical Center, Israel.
1986 - 1990    - Deputy Director of the Sheba Medical Center and Director of the Rehabilitation Hospital -

                            The Sheba Medical Center, Israel.
1990 - 1993    - Director General, The Tel-Aviv Sourasky Medical Center.

                             Member of the Scientific Committee of the Interdisciplinary Center

                             for Technological Analysis and Forecasting at Tel-Aviv University.
1993 - 1996    - Director General, (Surgeon General) The Ministry of Health.

                            Chairman, Israeli National Transplant Center.
1996-Present - Director General, The Tel-Aviv Sourasky Medical Center

ACADEMIC AND PROFESSIONAL AWARDS:
1984 - 1985 -    Kellogg Fellow in Health Services Administration, Kellogg Foundation.

ACTIVE PARTICIPATION IN SCIENTIFIC MEETINGS:
1. Barbash GI, Bar-Meir S, Bar-Shani, S, & Gilon O.
The prevalence of elevated serum alanin amino transferase among blood donors in Israel and its significance. 12th Congress of the Israel Medical Association 1982.

2. Barbash GI, Hod H, Roth A, Rath S, Har-Zahav Y, Rabinowitz B, & Seligsohn U.
Cycles of reocclusion-reperfusion during rt-PA treatment in patients with acute myocardial infarction.
Presented at the Thrombosis and Hemostasis conference, Brussels, July 1987.

3. Barbash GI, Hod H, Miller HI, Roth A, Rath S, Har-Zahav Y, Rabinowitz B, Laniado S, & Seligsohn U.
The Israeli study of early intervention in myocardial infarction; intravenous rt-PA with subsequent mechanical revascularization.
Presented at the Thrombosis and Hemostasis conference, Brussels, July 1987.

4. Roth A, Barbash GI, Hod H, Miller HI, Keren G, Laniado S, & Seligsohn U. Bleeding complications during rt-PA thrombolysis related to use of anti-inflammatory drugs prior to acute myocardial infarction admission.
Presented at the Thrombosis and Hemostasis conference, Brussels, July 1987.

5. Barbash GI.
Early administration of intravenous rt-PA thrombolysis in acute myocardial infarction. Combination of pre-hospital with hospital treatment.
Presented in the symposium on “Principles and advances in thrombolytic therapy” in the fifth joint meeting of the European Society of Cardiology, Spain, September 1987.

6. Barbash GI, Hod H, Rath S, Roth A, Miller HI, Modan M, Seligsohn U, Rabinowitz B, Laniado S.
The Israeli study of early intervention in myocardial infarction; intravenous rt-PA with delayed mechanical revascularization. Preliminary results. Presented in the American Heart Association Meeting, Anaheim, November 1987.

7. Barbash GI, Hod H, Rath S, Seligsohn U, Battler A, Har-Zahav Y, Modan M, Rabinowitz B.
Intermittent, dose-related reocclusion during infusion of recombinant tissue plasminogen activator in myocardial infarction patients.
Presented in the American Heart Association Meeting, Anaheim, November 1987.

8. Roth A, Barbash GI, Hod H, Miller HI, Rath S, Modan M, Behar S, Rabinowitz B, Laniado S.
Effectiveness and safety of intravenous tissue plasminogen activator thrombolysis by mobile intensive care units in acute myocardial infarction. Presented in the American College of Cardiology Meeting, Atlanta, March 1988.

9. Barbash GI, Hod H, Roth A, Miller HI, Rath S, Har-Zahav Y, Agranat O, Modan M, Rabinowitz B, Laniado S, Seligsohn U.
Association between fibrinolytic parameters and coronary patency in AMI patients treated with rt-PA thrombolysis.
Presented in the American Heart Association Meeting, Washington, November 1988.

10. Barbash GI, Roth A, Hod H, Rath S, Miller HI, Kuznitz F, Har-Zahav Y, Agranat O, Modan M, Motro M, Keren G, Battler A, Kaplinsky E, Rabinowitz B, Laniado S.
Significance of rapid ST-resolution to predict short and long-term outcome of AMI patients undergoing rt-PA thrombolysis.
Presented in the American Heart Association Meeting, Washington, November 1988.

11. Barbash GI, Hod H, Roth A, Modan M, Miller HI, Rath S, Har-Zahav Y, Agranat O, Keren G, Motro M, Shachar A, Basan S, Rabinowitz B, Laniado S, Kaplinsky E.
Randomized controlled trial of late in-hospital angiography and angioplasty vs. conservative management after rt-PA treatment in acute myocardial infarction.
Presented in the American College of Cardiology Meeting, New Orleans, March 1990.

12. Barbash GI.
Results of the GISSI and International t-PA/STK Trial.
Annual Meeting of Spanish National Association of Cardiology, Madrid, May 1990.

13. Barbash GI.
Discussion of the results of international trials in thrombolytic therapy of cardiovascular diseases.
Meeting of the National Italian Association of Pharmaco-therapy Cardiologists, Padua, May 1990.

14. Barbash GI.
Pre-hospital administration of thrombolytic therapy.
Annual Meeting of the Italian National Association of Hospital Cardiologists, Bologna, June 1990.

15. Barbash GI, Eisenberg MJ, Hod H, Roth A, Shachar A, Modan M, Zolti L, Kaplinsky E, Laniado S, Rabinowitz B.
The prognostic importance of late Q-wave development following thrombolytic therapy for acute myocardial infarction.
Presented in the American College of Cardiology Meeting, Atlanta, March 1991.

16. Matetzky S, Barbash GI, Shahar A, Rabinowitz B, Rath S, Har-Zahav Y, Agranat O, Kaplinsky E, Hod H.
The prognostic significance of early inversion T-waves after thrombolytic therapy for acute myocardial infarction.
Presented in the American Heart Association Meeting, Anaheim, November 1991.

17. Barbash GI, White H, Diaz R, Hampton JR, Heikkila J, Kristinsson A, Moulopoulos S, Paolasso EAC, Pehrsson K, Sandoe E, Simes J, Wilcox RG, Verstraete M, Von der Lippe G, Van der Werf T, Van de Werf F.
Pre-infarction angina pectoris predicts worse outcome after myocardial infarction in patients receiving thrombolytic therapy - experience gathered in the International TPA/STK Trial.
Presented in the American College of Cardiology Meeting, Dallas, April 1992.

18. Barbash GI, Goldbourt U, Modan M, White H, Diaz R, Hampton JR, Heikkila J, Kristinsson A, Moulopoulos S, Paolasso EAC, Pehrsson K, Sandoe E, Simes J, Wilcox RG, Verstraete M, Von der Lippe G, Van de Werf F.
Comparative mortality analysis of the International TPA/STK Trial. An unexplained variance.
Presented in the American College of Cardiology Meeting, Dallas, April 1992.

19. Barbash GI.
Rescue thrombolysis.
Presented in the International Symposium on Update in Thrombolysis, Hannover, October 1992.

20. Barbash GI, White H, Modan M, Van de Werf F.
Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic therapy. Presented in the American College of Cardiology Meeting, Anaheim, March 1993.

21. Gottlieb S, Barbash GI, Khoury Z, Behar S, on behalf of the Israeli Thrombolytic Study Group. Effect of advanced age on use of thrombolytic therapy and mortality in acute myocardial infarction.
Presented in the European Cardiology Society Meeting, Nice, France, September 1993.

22. Barbash GI, for the Israeli investigators.
Rescue thrombolysis in reinfarction.
Presented in the American Heart Association Meeting, Anaheim, November 1993.

23. Col J, White HD, Aylward P, Barbash GI, for the GUSTO Trial Investigators.
Effects of intravenous versus subcutaneous heparin as adjunctive therapy to streptokinase: Results of the GUSTO Trial.
Presented in the Am Heart Association Meeting, Anaheim, November 1993.

24. White HD, Barbash GI, Modan M, Simes J, Van de-Werf F, for the investigators of the International Mortality Trial.
After correcting for worse baseline characteristics, women treated with thrombolytic therapy for acute myocardial infarction have the same mortality and morbidity as men, except for a higher incidence of hemorrhagic stroke. Presented in the Am Heart Association Meeting, Anaheim, November 1993.

25. Behar S, Barbash GI, Goldbourt U, and the SPRINT and Thrombolytic Study Groups. Have changes in the management of acute myocardial infarction between the 80’s and 90’s reduced mortality?
Presented in the Am Heart Association Meeting, Anaheim, November 1993.

26. Behar S, Barbash GI, for the Israeli Thrombolytic Study Groups. Group use of coronary procedures in patients with acute myocardial infarction hospitalized in centers with and without coronary angiography facilities in Israel.
Presented in the American College of Cardiology Meeting, Atlanta, March 1994.

27. Barbash GI, White HD, Gore JM, Granger C, Weaver WD, Simoons ML, Aylward P, Van de Werf F, for the GUSO Trial Investigators.
More aggressive thrombolytic treatment increases stroke risk: results from the GUSTO trial.
Presented in the American College of Cardiology Meeting, Atlanta, March 1994.

28. Gore JM, Barbash GI, White HD, Granger C, Weaver WD, Simoons ML, Aylward P, Van de Werf F, for the GUSTO Trial. Functional status following stoke after thrombolytic therapy-results from the GUSTO trial.
Presented in the American College of Cardiology Meeting, Atlanta, March 1994.

29. Barbash GI, Ohman EM, White HD, Granger C, Califf RM, for the GUSTO Investigators. Rescue thrombolysis for suspected reinfarction following thrombolytic therapy: experience from the GUSTO trial. Presented in the American College of Cardiology Meeting, Atlanta, March 1994.

30. Behar S, Barbash GI, for the Israeli Thrombolytic Survey Group. Use of coronary procedures in patients with acute myocardial infarction hospitalized in centers with and without coronary angiography facilities in Israel. Presented in the American College of Cardiology Meeting, Atlanta, March 1994.

31. Barbash GI, Reiner JS, Granger CB, White HD, Lundergan CF, Ross AM, for the GUSTO Investigators. Smoking and Acute Myocardial Infarction Survival: Demographic and Quantitative Angiographic Foundations for the “Smoker’s Paradox”.
Presented in the American Heart Association Meeting, Dallas, November 1994.

32. Gottlieb S, Goldbourt U, Barbash GI, Boyko V, Behar S, the SPRINT and the Israeli Thrombolytic Survey Group.
The Prognosis of Elderly (³75) Patients Hospitalized With Acute Myocardial Infarction From 1981-83 to 1992 in Israel. Presented in the American Heart Association Meeting, Dallas, November 1994.

33. White HD, Granger C, Gore J, Barbash GI, for the GUSTO Investigators. Older Age is Associated With a Large Increase in Mortality and Total Stroke, but Not Non-fatal Disabling Stroke: Results of the GUSTO trial.
Presented in the American Heart Association Meeting, Dallas, November 1994.

MEMBERSHIP IN PROFESSIONAL SOCIETIES: